These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26772398)

  • 41. Carboxypeptidase A4 accumulation is associated with an aggressive phenotype and poor prognosis in triple-negative breast cancer.
    Handa T; Katayama A; Yokobori T; Yamane A; Fujii T; Obayashi S; Kurozumi S; Kawabata-Iwakawa R; Gombodorj N; Nishiyama M; Asao T; Shirabe K; Kuwano H; Oyama T
    Int J Oncol; 2019 Mar; 54(3):833-844. PubMed ID: 30628666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
    Xu X; Zhang L; He X; Zhang P; Sun C; Xu X; Lu Y; Li F
    Biochem Biophys Res Commun; 2018 Jul; 502(1):160-165. PubMed ID: 29792857
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metalloprotease-dependent activation of EGFR modulates CD44
    Wise R; Zolkiewska A
    Breast Cancer Res Treat; 2017 Nov; 166(2):421-433. PubMed ID: 28791489
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Features of CD44+/CD24-low phenotypic cell distribution in relation to predictive markers and molecular subtypes of invasive ductal carcinoma of the breast.
    Gudadze M; Kankava Q; Mariamidze A; Burkadze G
    Georgian Med News; 2014 Mar; (228):81-7. PubMed ID: 24743129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.
    Kapucuoğlu N; Bozkurt KK; Başpınar Ş; Koçer M; Eroğlu HE; Akdeniz R; Akçil M
    Pathol Res Pract; 2015 Oct; 211(10):740-7. PubMed ID: 26298632
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phenotypic, structural, and ultrastructural analysis of triple-negative breast cancer cell lines and breast cancer stem cell subpopulation.
    Moreira MP; Brayner FA; Alves LC; Cassali GD; Silva LM
    Eur Biophys J; 2019 Oct; 48(7):673-684. PubMed ID: 31485678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aldehyde dehydrogenase 1 (ALDH1) expression is an independent prognostic factor in triple negative breast cancer (TNBC).
    Ma F; Li H; Li Y; Ding X; Wang H; Fan Y; Lin C; Qian H; Xu B
    Medicine (Baltimore); 2017 Apr; 96(14):e6561. PubMed ID: 28383433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CD109 is a potential target for triple-negative breast cancer.
    Tao J; Li H; Li Q; Yang Y
    Tumour Biol; 2014 Dec; 35(12):12083-90. PubMed ID: 25149155
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
    Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
    Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer.
    He JH; Luo RZ; Cai MY; Li M; Lu JB; Yuan ZY
    Med Oncol; 2013 Mar; 30(1):468. PubMed ID: 23345115
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are CD44
    Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
    Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer.
    Ji S; Yu H; Zhou D; Fan X; Duan Y; Tan Y; Lang M; Shao G
    J Transl Med; 2023 Oct; 21(1):721. PubMed ID: 37838657
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Autophagy of cancer stem cells is involved with chemoresistance of colon cancer cells.
    Wu S; Wang X; Chen J; Chen Y
    Biochem Biophys Res Commun; 2013 May; 434(4):898-903. PubMed ID: 23624503
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD24 Expression and differential resistance to chemotherapy in triple-negative breast cancer.
    Deng X; Apple S; Zhao H; Song J; Lee M; Luo W; Wu X; Chung D; Pietras RJ; Chang HR
    Oncotarget; 2017 Jun; 8(24):38294-38308. PubMed ID: 28418843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients.
    Obayashi S; Horiguchi J; Higuchi T; Katayama A; Handa T; Altan B; Bai T; Bao P; Bao H; Yokobori T; Nishiyama M; Oyama T; Kuwano H
    Int J Oncol; 2017 Sep; 51(3):781-790. PubMed ID: 28766688
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
    Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
    Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sulforaphane Suppresses the Growth of Triple-negative Breast Cancer Stem-like Cells
    Castro NP; Rangel MC; Merchant AS; MacKinnon G; Cuttitta F; Salomon DS; Kim YS
    Cancer Prev Res (Phila); 2019 Mar; 12(3):147-158. PubMed ID: 30679159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclooxygenase-2 regulates TGFβ-induced cancer stemness in triple-negative breast cancer.
    Tian J; Hachim MY; Hachim IY; Dai M; Lo C; Raffa FA; Ali S; Lebrun JJ
    Sci Rep; 2017 Jan; 7():40258. PubMed ID: 28054666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.